UK Markets closed

Transgene SA (0OCQ.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.0400+0.5500 (+22.09%)
At close: 2:05PM BST
Sign in to post a message.
  • C
    I recently bought some shares of Transgene. This quarter Transgene will come with the first efficacy data about their clinical trials with their TG4010 in combination of BMS PD-L1 inhibitor Opdivo in advanced Non small Lung Cancer: first line, in combination with chemo (NCT03353675), second line: previously treated patients (NCT02823990). Transgene already had a successful phase 2 with TG4010 as a combination treatment with chemo (1,2) but decided not to pursue a phase 3 trial, but to start a phase 2 with the combination of checkpoint inhibitors. The price of Transgene recently dropped when their oncolytic virus for liver failed. This was in combination with Sorafenib. Nevertheless I am putting some money on the combination with checkpoint inhibitors.. Furthermore Transgene generates considerable money by offering their virus technology, see for example their recent collaboration with Astrazeneca (AZN) for 5 new oncolytic viruses for which AZN defines the transgenes.

  • B
    Bioscience NL
    November 7, 2018 - Transgene and BioInvent present positive data at the SITC, supporting the co-development of a next-generation oncolytic virus encoding for an anti-CTLA-4 antibody
    November 7, 2018 - Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
    October 30, 2018 - NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform
  • R
    another 20 year nothing. ;(
  • R
    june 22, '20 +25% (?)
  • R
    new immnuno something goes into phase 1 v corectal cancer. glad they are still trying.